CH50 as a putative biomarker of eculizumab treatment in neuromyelitis optica spectrum disorder

Chihiro Namatame, Tatsuro Misu, Yoshiki Takai, Shuhei Nishiyama, Ichiro Nakashima, Kazuo Fujihara, Masashi Aoki

Research output: Contribution to journalArticlepeer-review

Abstract

Here we report 3 cases of neuromyelitis optica spectrum disorder (NMOSD), who were all treated with eculizumab and could be observed with monitoring serum C3, C4 and 50% hemolytic complement (CH50) before and after the treatment. Serum C3 and C4 were not dramatically changed during the treatment, in contrast serum CH50 level of each patient had diminished and kept under the detection limit after the treatment without clinical worsening, even in the situation of extending dosing. Serum CH50 level is useful to monitor the drug efficacy during eculizumab treatment.

Original languageEnglish
Article numbere05899
JournalHeliyon
Volume7
Issue number1
DOIs
Publication statusPublished - 2021 Jan

Keywords

  • 50% hemolytic complement
  • Astrocytopathy
  • Biomarker
  • C3
  • C4
  • C5
  • CH50
  • Eculizumab
  • Neuromyelitis Optica
  • Neuromyelitis optica spectrum disorder

ASJC Scopus subject areas

  • General

Fingerprint Dive into the research topics of 'CH50 as a putative biomarker of eculizumab treatment in neuromyelitis optica spectrum disorder'. Together they form a unique fingerprint.

Cite this